Tirzepatide, a novel dual GIP and GLP-1 receptor agonist, has not been established as a standard treatment for Cluster Headache, and current evidence is limited. While its primary metabolic effects involve glucose regulation and weight reduction, its potential efficacy in cluster headache management would require further clinical research to definitively characterize its neurological mechanisms and therapeutic potential.